Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study

Martínez‐Montoro, José Ignacio; Picón-César, María José; Simón-Frapolli, Víctor José; Pinzón-Martín, José Luis; Garcı́a-Alemán, Jorge; Durán-Martínez, María; Tinahones, Francisco J.

doi:10.2337/dc23-0083

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, it is necessary to accumulate the effects of dapagliflozin in type 1 diabetes patients. Indeed, Martínez‐Montoro et al 35 . reported the benefit of dapagliflozin combination therapy in a retrospective analysis of 38 participants with type 1 diabetes treated with dapagliflozin at two centers.…”

Section: Discussionmentioning

confidence: 99%

“…Correlation (Pearson's correlation coefficient) between changes in glycemic control parameters and changes in body compositionMontoro et al35 reported the benefit of dapagliflozin combination therapy in a retrospective analysis of 38 participants with type 1 diabetes treated with dapagliflozin at two centers. Both nutritional statuses, including protein intake and the amount of exercise, were not considered.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus

Yoshimura

Hashimoto

Okada

et al. 2023

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/IntroductionDapagliflozin is used for individuals with type 1 diabetes, although the effect of this medication on skeletal muscle mass is not well established. In addition, there are few studies examining the effects of good glycemic control on skeletal muscle mass in type 1 diabetes patients. We investigated changes in glycemic control and skeletal muscle mass with dapagliflozin in individuals with type 1 diabetes, and the association between these changes.Materials and MethodsThis was a post‐hoc analysis of a multicenter, open‐label, non‐randomized, prospective, interventional study in individuals with type 1 diabetes. The participants received dapagliflozin at 5 mg/day for 4 weeks, and were reviewed before and after treatment. Weight‐ and height‐corrected appendicular skeletal muscle mass (ASM) were calculated as indices of skeletal muscle mass using bioelectrical impedance analysis.ResultsA total of 36 individuals were included in the analysis. After the 4 weeks of dapagliflozin treatment, ASM/height2 decreased in the body mass index <23 group (P = 0.004). ASM / weight decreased in all men aged >60 years. The change in ASM / weight (%) was negatively correlated with the change in glycated hemoglobin (%;P = 0.023). The change in ASM / height2 (kg/m2) was also positively correlated with the change in time within the glucose range of 70–180 mg/dL (P = 0.036).ConclusionDapagliflozin treatment of individuals with type 1 diabetes, particularly non‐obese individuals and older men, might result in loss of skeletal muscle mass. However, good glycemic control during treatment might prevent the onset and progression of sarcopenia.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%